HCW Biologics files pre-funded warrant 4.1 form.
Documents a form for pre-funded warrants indicating shares for purchase and an initial exercise date of 2026; these instruments typically support capital raising efforts.
View filing at SEC.gov →4 most recent filings and news items mentioning HCWB. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/HCWB/news?limit=20"
Pull HCWB filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayDocuments a form for pre-funded warrants indicating shares for purchase and an initial exercise date of 2026; these instruments typically support capital raising efforts.
View filing at SEC.gov →The company regained compliance with Nasdaq's bid price rule after completing a mandatory one-for-six reverse stock split. This reinstatement is subject to a monitoring period through June 17, 2027.
View filing at SEC.gov →HCW Biologics announced positive preliminary results from its Phase 1 clinical trial of HCW9302, with all three patients in the second dose cohort showing ≥25% improvement in alopecia severity scores and no dose-limiting toxicities reported. The well-tolerated results support the
View filing at SEC.gov →HCW Biologics exercised its option to regain exclusive ex vivo rights to HCW9206 and HCW9201 compounds from Wugen at no cost while retaining upfront fees including 2.2M Wugen shares. The move positions the company to commercialize CAR-T manufacturing reagents that published data
View filing at SEC.gov →